Scientists from the Children’s Hospital of Philadelphia (CHOP) report that they have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a ...

Acute lymphoblastic leukemia (ALL) manifests as a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood and eventually extramedullary sites. While mostly ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

Acute lymphoblastic leukemia (ALL) is known as a pediatric leukemia, with approximately half of cases occurring in children. ALL is the most common childhood malignancy, representing 75% to 80% of ...

The first leukaemia patient to receive a breakthrough treatment since it was made available on the NHS has said it was ...

A new cell therapy, targeting CD7 on leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment ...

The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell ...